Inside the research
Haemonetics Corporation
HAE Research profile · latest available data
Price overview
$105.30
▼ -0.70 (-0.7%)
| 52w hi | $108.80 |
|---|---|
| 52w lo | $47.67 |
| Vol | 492.60K |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.53
| Short | +0.57 |
|---|---|
| Medium | +0.64 |
| Long | +0.21 |
computed 2026-09-27
Key fundamentals
Haemonetics Corporation
Healthcare · Medical Devices
| Market cap | $4.79B |
|---|---|
| Enterprise value | $5.74B |
| Trailing P/E | 50.87x |
| Forward P/E | 18.23x |
| EV / EBITDA | 16.00x |
| P / S (ttm) | 3.54x |
| Profit margin | 7.1% |
| Return on equity | 11.2% |
| Revenue growth | +5.6% |
| Earnings growth | +2.9% |
| Debt / equity | 140.26 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.15 | |
| Sector | +0.08 | |
| Technical | +0.43 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
Risk Metrics
| Beta vs SPX | 0.57 |
|---|---|
| Corr SPX | 0.19 |
| Annual vol | 46.8% |
| Annual ret | +27.9% |
| Sharpe | 0.60 |
| Max DD | -49.0% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-06 | Earnings Release, Exhibits | read |
| 2026-07-28 | Officer / Director Change, Shareholder Vote… | read |
| 2026-06-05 | Reg FD Disclosure, Exhibits | read |
| 2026-05-07 | Earnings Release, Exhibits | read |
| 2026-05-01 | Officer / Director Change | read |
| 2026-03-03 | Reg FD Disclosure | read |
| 2026-02-12 | Reg FD Disclosure | read |
| 2026-02-05 | Earnings Release, Exhibits | read |
| 2026-01-09 | Other Material Event, Exhibits | read |
| 2025-11-06 | Earnings Release, Exhibits | read |
| 2025-08-07 | Earnings Release, Exhibits | read |
| 2025-07-25 | Shareholder Vote | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-24 | Madaus Martin D | Grant | 2.54K | — | |
| 2026-07-24 | Zane Ellen M | Grant | 2.54K | — | |
| 2026-07-24 | Pomeroy Claire | Grant | 2.54K | — | |
| 2026-07-24 | KROLL MARK W | Grant | 2.54K | — | |
| 2026-07-24 | Johnson Lloyd Emerson | Grant | 2.54K | — | |
| 2026-07-24 | COYLE MICHAEL J | Grant | 2.54K | — | |
| 2026-07-24 | Bryant Diane M | Grant | 2.54K | — | |
| 2026-07-24 | ABERNATHY ROBERT E | Grant | 2.54K | — | |
| 2026-06-05 | Maunsell Farris Maryanne | VP, Chief Accounting Offi | Withheld for tax | 259 | $18.46K |
| 2026-06-05 | Miller Laurie A. | SVP, Human Resources | Withheld for tax | 313 | $22.31K |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 0 |
| Top-5 share | 0.0% |
| HHI | 0 (—) |
SEC Filings
The Long Run
FY 2010–2025 · 15 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $1.36B | +9.6% | |
| Gross profit | $615.10M | +5.1% | |
| Operating income | $164.88M | +5.6% | |
| Net income | $115.40M | +6.2% | |
| Cash from ops | $181.75M | +2.8% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $105.72 | $106.58 | $104.71 | $105.30 | 492.60K |
| Sep 24 | $106.67 | $108.22 | $105.92 | $106.00 | 416.80K |
| Sep 23 | $108.56 | $110.28 | $106.70 | $106.82 | 704.90K |
| Sep 22 | $109.26 | $110.14 | $108.38 | $108.52 | 446.60K |
| Sep 21 | $109.24 | $110.06 | $108.05 | $108.73 | 327.00K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →